After the release of our interim results this week, we're pleased to share another interview between N4 Pharma's CEO, Nigel Theobald, and Directors Talk. Nigel discusses the progress made with Nuvec® research projects in the last half and explains our strategy as we move forward with our work – [...]
N4 Pharma's CEO, Nigel Theobald, has spoken to Directors Talk to give an update on our Covid-19 proof of concept project, and our ongoing work to show Nuvec®'s potential use with multiple vaccines. Watch the interview in full below or read the article. https://vimeo.com/457689117
Our latest article in the May issue of ONdrugDelivery features our CEO, Nigel Theobald, discussing the challenges of oligonucleotide delivery and explores approaches to overcome them. Head to page 68-72 to read more.
The March issue of Pharma's Almanac features our CEO, Nigel Theobald, discussing the advantages of silica and our work with Nuvec® to improve drug delivery systems for nucleic acid-based cancer immunotherapies and viral vaccines. Click here to read more.
Over the last three decades, rapid progress in molecular biology has led to nucleic acids, such as plasmid DNA (pDNA), messenger RNA (mRNA) and, small interfering/silencing RNA (siRNA), being proposed for use as therapeutic agents. Our latest whitepaper underlines recent work in the field and details the extensive research [...]
Our CEO, Nigel Theobald, recently provided an update on our Nuvec® program following the release of our interim results. You can watch the full interview with Proactive London's Andrew Scott below or visit the website: https://bit.ly/2lU6O78. https://www.youtube.com/watch?time_continue=776&v=TJVlEOs8TEE
Our CEO, Nigel Theobald, recently caught up with The Medicine Maker to discuss the story behind N4 Pharma and give his advice to entrepreneurs in the pharmaceutical industry. Click here to create your logins and read the full article.
N4 Pharma has been featured in the latest issue of BioPharm International.
Nigel Theobald, CEO of N4 Pharma, has spoken to Dr. Kevin Robinson at Manufacturing Chemist magazine about how the company has developed Nuvec® and the impact it could have for vaccines and cancer treatments.